The Healthcare sector is made up of devices and systems that support healthcare organizations such as hospitals, doctor’s offices, surgical centers, and more. Healthcare technologies range from equipment like imaging machinery and robotic surgical assistants to patient recordkeeping applications and scheduling support. Register today to discover how Forge can help you buy and sell private shares.
Register to add companies to your watchlist and get access to bids/asks activity, last matched price and trade eligibility details.
Register| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4 |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids | $ Total Asks | # Bids | # Asks | Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
| SetPoint Medical | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $303.01MM | Series D | 8/11/2025 | $115MM | $471.62MM | $1.51 | Elevage Medical Technologies, Ally Bridge Group, Northwell Health, SPRIG Equity, Norwest Venture Partners, New Enterprise Associates, Viking Global Investors, Action Potential Venture Capital, Abbott, Boston Scientific, Euclidean Capital, Richard King Mellon Foundation, Morgenthaler Ventures, ShangBay Capital, Ascendum Capital, Catalio Capital Management, Gilmartin Capital, Midas Capital | |||||
| Ansun Biopharma | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $165.2MM | Series B | 8/15/2018 | $100MM | $466.82MM | $1.49 | Lilly Asia Ventures, Matrix Partners China, Yuanming Capital, Lyfe Capital, 3E Bioventures | |||||
| GenapSys | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $201.18MM | Series D | 5/27/2021 | $70MM | $463.55MM | $7.84 | Farallon Capital Management, Soleus Capital | |||||
| Capsule | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $180.56MM | Series E | 2/13/2023 | $100MM | $458.12MM | $2.93 | Cox Enterprises, SeedFord Partners | |||||
| Cue Health | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $179.56MM | Series C-1 | 6/10/2020 | $100MM | $455.86MM | $3.66 | Decheng Capital, Foresite Capital, Madrone Capital Partners, Johnson & Johnson Innovation, ACME Capital | |||||
| Akili | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $275.08MM | Series D | 5/26/2021 | $151.68MM | $452.34MM | $8.43 | Neuberger Berman Funds, Polaris Partners, Mirae Assets, Shionogi & Co LTD, New Leaf Venture Partners, Dave Baszucki, QUAD Investment Management, Ladera Venture Partners, Temasek, Baillie Gifford, JAZZ Venture Partners, Evidity Health Capital, Omidyar Technology Ventures, Fearless Ventures, Amgen Ventures, M Ventures | |||||
| VitalConnect | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $308.06MM | Series G-1 | 2/19/2025 | $33.85MM | $451.12MM | $0.42 | Ally Bridge Group, EW Healthcare Partners, MVM Life Sciences, Revelation Partners | |||||
| Chroma Medicine | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $262MM | Series B | 3/1/2023 | $135MM | $450.56MM | $2.60 | ARCH Venture Partners, DCVC Bio, Mubadala Capital, Sixth Street, Alexandria Venture Investments, Atlas Venture, Casdin Vapital, Cormorant Asset Management, Janus Henderson Investors, Newpath Partners, Omega Funds, Osage University Partners, Sofinnova Partners, T Rowe Price, Wellington Management | |||||
| EndoGastric Solutions | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $377.99MM | Series J | 11/25/2020 | $27MM | $448.42MM | $2.51 | Vertex Growth Fund | |||||
| Geneoscopy | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $163.58MM | Series C | 1/8/2025 | $79.05MM | $447.85MM | $4.13 | Bio-Rad Laboratories, Petrichor, Labcorp, Morningside Ventures, Lightchain Capital, NT Investments, Granger Management, Mercy Health, Tri Locum Partners | |||||
| Diagonal Therapeutics | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $253MM | Series B | 1/8/2026 | $125MM | $447.42MM | $2.70 | Sanofi Ventures, Janus Henderson Investors, Deep Track Capital, EcoR1 Capital, Logos Capital, Balyasny Asset Management, Woodline Partners, BVF Partners, Atlas Venture, Lightspeed Venture Partners, RA Capital Management, Frazier Life Sciences, Viking Global Investors, Velosity Capital, Checkpoint Capital, RV Invest, Biovision Ventures | |||||
| Taiga Biotechnologies | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $42.83MM | Series C | 5/31/2019 | $27.2MM | $442.88MM | $6.80 | Undisclosed Investors | |||||
| BioAge | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $1.42B | Series D | 2/13/2024 | $170MM | $440.23MM | $3.42 | Sofinnova Investments, Longitude Capital, RA Capital, Cormorant Asset Management, RTW Investments, SV Health Investors, OrbiMed Advisors, Sands Capital, Pivotal bioVenture Partners, Osage University Partners, Lilly Ventures, Amgen Ventures, Andreessen Horowitz | |||||
| GRIN Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $276.16MM | Series D | 5/27/2025 | $140MM | $439.01MM | $1.79 | Angelini Pharma, Blackstone Life Sciences | |||||
| Frontier Medicines | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $255.5MM | Series C | 6/25/2024 | $100MM | $438.18MM | $2.34 | Deerfield Management Company, Droia Ventures, Galapagos NV, DCVC, MPM Capital, RA Capital Management, Deep Track Capital, ArrowMark Partners | |||||
| CoRegen | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $131.75MM | Series B-1 | 10/28/2025 | $13.5MM | $437.24MM | $18.00 | Undisclosed Investors | |||||
| Harbor Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $384.26MM | Series A-4-4 | 2/20/2026 | $45MM | $436.68MM | $0.71 | Undisclosed Investors | |||||
| Aiolos Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $247.55MM | Series A | 10/24/2023 | $180MM | $436.12MM | $1.19 | Atlas Venture, Bain Capital Life Sciences, Forbion, Sofinnova Investments, RA Capital Management | |||||
| Tome Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $245.57MM | Series B | 12/12/2023 | $150MM | $435.54MM | $3.03 | Andreessen Horowitz, ARCH Venture Partners, GV, Longwood Fund, Polaris Partners, Bruker Corporation, FUJIFILM Corporation, Alexandria Venture Investments | |||||
| Supira Medical | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $241.09MM | Series E | 3/26/2025 | $120MM | $431.99MM | $1.35 | Novo Holdings, Qatar Investment Authority, Cormorant Asset Management, TCP, 415 Capital, AMED Ventures, Picard Angst, Unorthodox Ventures | |||||
| Genesis Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $308.66MM | Series B | 8/10/2023 | $200MM | $430.19MM | $5.11 | Andreessen Horowtiz, Fidelity, BlackRock, Nventures, T. Rowe Price Associates, Rock Springs Capital, Radical Ventures, Menlo Ventures | |||||
| Apnimed | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $259.52MM | Series D-1 | 12/8/2025 | $35MM | $429.39MM | $9.66 | Undisclosed Investors | |||||
| Attralus | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $344MM | Series B | 2/6/2024 | $172.6MM | $428.81MM | $7.76 | Logos Capital, Janus Henderson Investors, Redmile Group, Samsara BioCapital, Sarissa Capital Management, Surveyor Capital, Vivo Capital, venBio Partners, Alpha Wave Ventures, Bristol Myers Squibb | |||||
| Asher Biotherapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $1.05B | Series C | 4/16/2024 | $55MM | $428.78MM | $1.16 | RA Capital, AstraZeneca, Bristol Myers Squibb, Janus Henderson Investors, Third Rock Ventures, Wellington Management, Boxer Capital | |||||
PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES
Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
Post-Money Valuation (valuation) represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
Market activity indicates the level of activity for a company based on recent IOIs, secondary transactions, and pending transactions.
Sector and subsector descriptions focus primarily on the types of companies within the respective sectors and subsectors that are typically available through Forge Markets. Any sector or subsector as a whole may include companies that participate in business lines in other sectors or subsectors. Companies are classified into sectors and subsectors according to the problem(s) they seek to solve rather than the method by which the solution is delivered.